Clinical Trials Browser

Terminated × INDUSTRY × spebrutinib × Clear all

NCT02031419 2024-01-18

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Phase 1 Terminated

Lymphoma, Lymphoma, Large B-Cell, Diffuse